Research Article
Physical Activity across Frailty Phenotypes in Females with Parkinson’s Disease
Table 1
Participant characteristics across frailty phenotypes in PD and non-PD females.
| | PD | Non-PD | | Nonfrail | Prefrail | Frail | Nonfrail | Prefrail | Frail |
| | 4 | 7 | 4 | 8 | 4 | 3 | Age | 69 ± 1 | 65 ± 10 | 63 ± 11 | 63 ± 8ab | 79 ± 14b | 90 ± 6 | Body mass index (kg/m2) | 26.31 ± 5.6 | 22.95 ± 4.3 | 25.06 ± 4.3 | 23.20 ± 5.7 | 34.60 ± 5.4 | 32.49 ± 12.2 | Number of medications | 4.0 ± 2.0 | 2.9 ± 1.5 | 3.3 ± 2.6 | 1.3 ± 1.3 | 6.0 ± 4.2 | 5.3 ± 0.6 | mg carbidopa-levodopa per day | 366.67 ± 57.7 | 571.43 ± 340.2 | 825.00 ± 330.4 | | | | carbidopa-levodopa only () | 2 | 3 | 2 | | | | carbidopa-levodopa + pram () | 2 | 2 | 0 | | | | carbidopa-levodopa + enta () | 0 | 0 | 1 | | | | carbidopa-levodopa + enta + pram () | 0 | 1 | 1 | | | | carbidopa-levodopa + aman + rop () | 0 | 1 | 0 | | | | Hoehn & Yahr disease severity | 1.83 ± 0.8 | 1.86 ± 0.6 | 2.50 ± 0.4 | | | |
|
|
PD: Parkinson’s disease, : number, kg: kilogram, m: meter, mg: milligram, pram: pramipexole, enta: entacapone, aman, amantadine, and rop: ropinirole.
aSignificantly different from prefrail.
bSignificantly different from frail.
|